Cytokinetics gets an 'incremental' win for delayed heart drug

Cytokinetics’s aficamten is better than the standard of care in a heart muscle disease, the company said Tuesday. The development is positive, but with aficamten’s approval submission delayed, it will be ...

May 13, 2025 - 16:14
 0
Cytokinetics gets an 'incremental' win for delayed heart drug
Cytokinetics’s aficamten is better than the standard of care in a heart muscle disease, the company said Tuesday. The development is positive, but with aficamten’s approval submission delayed, it will be ...